Phase 3 Clinical Trials

Late-stage Phase 3 clinical trial results and data readouts for biotech companies.

100 UpcomingView Full Calendar

February 202619

days

4502.T⭐Phase 3$8.0T

TAK-881 Phase 3 Results Expected

TAK-881• Primary Immunodeficiency Diseases (PID)65

Feb 10

CT.gov

00%

DAWN⭐Phase 3$972M

Tovorafenib Phase 3 Results Expected

Tovorafenib• Low-grade Glioma400

Feb 15

CT.gov

00%

JNGHF⭐Phase 3

SHR-A1811 Phase 3 Results Expected

SHR-A1811• Advanced Non-small Cell Lung Cancer300

Feb 15

CT.gov

00%

KOD⭐Phase 3$76M

KSI-101 Phase 3 Results Expected

KSI-101• Macular Edema Secondary to Inflammation150

Feb 15

CT.gov

00%

OTSKF⭐Phase 3$34.0B

OPC-34712FUM/ Brexpiprazole fumarate Phase 3 Results Expected

OPC-34712FUM/ Brexpiprazole fumarate• Acute Schizophrenia450

Feb 15

CT.gov

00%

DAWN⭐Phase 3$972M

Chemotherapeutic Agent Phase 3 Results Expected

Chemotherapeutic Agent• Low-grade Glioma400

Feb 15

CT.gov

00%

AVDL⭐Phase 3$1.3B

FT218 Phase 3 Results Expected

FT218• Narcolepsy150

Feb 15

CT.gov

00%

JNGHF⭐Phase 3

Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin Phase 3 Results Expected

Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin• Non-Small Cell Lung Cancer With HER2- Mutations300

Feb 15

CT.gov

00%

CMPS⭐Phase 3$355M

Psilocybin Phase 3 Results Expected

Psilocybin• Treatment Resistant Depression572

Feb 15

CT.gov

00%

NMRA⭐Phase 3$824M

NMRA-335140 Phase 3 Results Expected

NMRA-335140• Major Depressive Disorder332

Feb 15

CT.gov

00%

PFE⭐Phase 3$142.7B

talazoparib plus enzalutamide Phase 3 Results Expected

talazoparib plus enzalutamide• Prostate Cancer599

Feb 18

CT.gov

00%

NVO⭐Phase 3$253.8B

Tirzepatide Phase 3 Results Expected

Tirzepatide• Diabetes Mellitus, Type 21,000

Feb 20

CT.gov

00%

NVO⭐Phase 3$253.8B

Semaglutide Phase 3 Results Expected

Semaglutide• Obesity1,000

Feb 20

CT.gov

00%

NVO⭐Phase 3$253.8B

Cagrilintide Phase 3 Results Expected

Cagrilintide• Obesity or Overweight1,000

Feb 20

CT.gov

00%

INCY⭐Phase 3$9.9B

Povorcitinib Phase 3 Results Expected

Povorcitinib• NonSegmental Vitiligo467

Feb 25

CT.gov

00%

NVS⭐Phase 3$274.7B

TQJ230 Phase 3 Results Expected

TQJ230• Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease8,323

Feb 26

CT.gov

00%

4503.T⭐Phase 3$4.0T

mirabegron Phase 3 Results Expected

mirabegron• Neurogenic Detrusor Overactivity7

Feb 28

CT.gov

00%

ADCT⭐Phase 3$173M

Loncastuximab Tesirine Phase 3 Results Expected

Loncastuximab Tesirine• Relapsed Diffuse Large B-Cell Lymphoma440

Feb 28

CT.gov

00%

NOVN.SW⭐Phase 3$221.6B

JDQ443 Phase 3 Results Expected

JDQ443• Non-Small Cell Lung Cancer95

Feb 28

CT.gov

00%

March 202656

WXI⭐Phase 3

CU-20101 treatment for Moderate to Severe Glabellar Striae Phase 3 Results Expected

CU-20101 treatment for Moderate to Severe Glabellar Striae• Glabellar Frown Lines554

Mar 1

CT.gov

00%

EPZM⭐Phase 3

Tazemetostat Phase 3 Results Expected

Tazemetostat• Diffuse Large B-cell Lymphoma (DLBCL)612

Mar 1

CT.gov

00%

VRDN⭐Phase 3$732M

VRDN-003 Phase 3 Results Expected

VRDN-003• Thyroid Eye Disease117

Mar 1

CT.gov

00%

AZN.L⭐Phase 3$217.4B

Tozorakimab Phase 3 Results Expected

Tozorakimab• Chronic Obstructive Pulmonary Disease (COPD)1,454

Mar 2

CT.gov

00%

NVS⭐Phase 3$274.7B

Ianalumab Phase 3 Results Expected

Ianalumab• Warm Autoimmune Hemolytic Anemia (wAIHA)

Mar 2

CT.gov

00%

AZN.L⭐Phase 3$217.4B

Capivasertib Phase 3 Results Expected

Capivasertib• Triple Negative Breast Neoplasms1,035

Mar 4

CT.gov

00%

AZN.L⭐Phase 3$217.4B

docetaxel Phase 3 Results Expected

Docetaxel• Prostate Cancer1,035

Mar 4

CT.gov

00%

MRK⭐Phase 3$245.9B

Intismeran autogene Phase 3 Results Expected

Intismeran autogene• Bladder Cancer46

Mar 5

CT.gov

00%

MRK⭐Phase 3$245.9B

Pembrolizumab Phase 3 Results Expected

pembrolizumab• Non-small Cell Lung Cancer46

Mar 5

CT.gov

00%

SNY⭐Phase 3$115.3B

avalglucosidase alfa Phase 3 Results Expected

avalglucosidase alfa• Glycogen Storage Disease Type II17

Mar 6

CT.gov

00%

SBFM⭐Phase 3$23M

Clifutinib Phase 3 Results Expected

Clifutinib• Leukemia, Acute Myeloid (AML)324

Mar 10

CT.gov

00%

2mo

ARGX⭐Phase 3$50.3B

efgartigimod Phase 3 Results Expected

Efgartigimod• Postural Orthostatic Tachycardia Syndrome101

Mar 11

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

docetaxel Phase 3 Results Expected

Docetaxel• Carcinoma, Non-Small-Cell Lung703

Mar 12

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

sigvotatug vedotin Phase 3 Results Expected

Sigvotatug Vedotin• Non-Small Cell Lung Cancer703

Mar 12

CT.gov

00%

2mo

BMY⭐Phase 3$84.2B

Repotrectinib Phase 3 Results Expected

Repotrectinib• Carcinoma, Non-Small-Cell Lung190

Mar 13

CT.gov

00%

2mo

INSM⭐Phase 3$11.0B

Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected

Treprostinil Palmitil Inhalation Powder• Pulmonary Hypertension31

Mar 14

CT.gov

00%

2mo

ITCI⭐Phase 3

Lumateperone Phase 3 Results Expected

Lumateperone• Major Depressive Disorder350

Mar 15

CT.gov

00%

2mo

LLY⭐Phase 3$769.8B

Orforglipron Phase 3 Results Expected

Orforglipron• Obesity2,749

Mar 15

CT.gov

00%

2mo

IMVT⭐Phase 3$1.9B

Batoclimab Phase 3 Results Expected

Batoclimab• Thyroid Eye Disease100

Mar 15

CT.gov

00%

2mo

KRYS⭐Phase 3$4.6B

Placebo Phase 3 Results Expected

KB801• Neurotrophic Keratitis16

Mar 15

CT.gov

00%

2mo

LLY⭐Phase 3$769.8B

Insulin Glargine Phase 3 Results Expected

Insulin Glargine• Diabetes Mellitus, Type 22,749

Mar 15

CT.gov

00%

2mo

KRYS⭐Phase 3$4.6B

KB803 Phase 3 Results Expected

KB803• Dystrophic Epidermolysis Bullosa16

Mar 15

CT.gov

00%

2mo

AARD⭐Phase 3$275M

ARD-101 Phase 3 Results Expected

ARD-101• Hyperphagia90

Mar 15

CT.gov

00%

2mo

OCUP⭐Phase 3

0.75% Phentolamine Ophthalmic Solution Phase 3 Results Expected

0.75% phentolamine ophthalmic solution• Presbyopia200

Mar 15

CT.gov

00%

2mo

MOLN⭐Phase 3$176M

[18F]florbetaben Phase 3 Results Expected

[18F]florbetaben• Cardiac Amyloidosis200

Mar 15

CT.gov

00%

2mo

MDGL⭐Phase 3$5.1B

Resmetirom Phase 3 Results Expected

Resmetirom• NASH1,000

Mar 15

CT.gov

00%

2mo

ABBV⭐Phase 3$300.2B

Azacitidine Phase 3 Results Expected

Azacitidine• Acute Myeloid Leukemia (AML)531

Mar 15

CT.gov

00%

2mo

ADVB⭐Phase 3$4M

[18F]PSMA-1007 Phase 3 Results Expected

[18F]PSMA-1007• Prostate Cancer380

Mar 15

CT.gov

00%

2mo

KPTI⭐Phase 3$108M

Selinexor Phase 3 Results Expected

Selinexor• Multiple Myeloma, Refractory353

Mar 15

CT.gov

00%

2mo

ABBV⭐Phase 3$300.2B

Venetoclax Phase 3 Results Expected

Venetoclax• Acute Myeloid Leukemia (AML)531

Mar 15

CT.gov

00%

2mo

NBIX⭐Phase 3$10.5B

Valbenazine Phase 3 Results Expected

Valbenazine• Tardive Dyskinesia154

Mar 15

CT.gov

00%

2mo

AMLX⭐Phase 3$117.6B

Avexitide Phase 3 Results Expected

Avexitide• Post Bariatric Hypoglycemia75

Mar 15

CT.gov

00%

2mo

RNA⭐Phase 3$10.8B

AOC 1001 (del-desiran) Phase 3 Results Expected

AOC 1001 (del-desiran)• DM1159

Mar 15

CT.gov

00%

2mo

KPTI⭐Phase 3$108M

Ruxolitinib Phase 3 Results Expected

Ruxolitinib• Myelofibrosis353

Mar 15

CT.gov

00%

2mo

SVA⭐Phase 3$642M

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV Phase 3 Results Expected

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV• Influenza150

Mar 15

CT.gov

00%

2mo

REGN⭐Phase 3$113.8B

Placebo Phase 3 Results Expected

Dupilumab• Atopic Dermatitis (AD)1,546

Mar 16

CT.gov

00%

2mo

REGN⭐Phase 3$113.8B

Pembrolizumab Phase 3 Results Expected

Pembrolizumab• Melanoma1,546

Mar 16

CT.gov

00%

2mo

REGN⭐Phase 3$113.8B

Cemiplimab Phase 3 Results Expected

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma1,546

Mar 16

CT.gov

00%

2mo

REGN⭐Phase 3$113.8B

Fianlimab Phase 3 Results Expected

Fianlimab• Melanoma1,546

Mar 16

CT.gov

00%

2mo

INCY⭐Phase 3$9.9B

Povorcitinib Phase 3 Results Expected

Povorcitinib• NonSegmental Vitiligo450

Mar 17

CT.gov

00%

2mo

IPSEY⭐Phase 3$12.9B

Elafibranor Phase 3 Results Expected

Elafibranor• Primary Biliary Cholangitis18

Mar 19

CT.gov

00%

2mo

WXI⭐Phase 3

Drug: 5 mg BGM0504 Administered SC Phase 3 Results Expected

Drug: 5 mg BGM0504 Administered SC• Type 2 Diabetes Mellitus (T2DM)537

Mar 20

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

Ritlecitinib Phase 3 Results Expected

Ritlecitinib• Stable Nonsegmental Vitiligo

Mar 22

CT.gov

00%

2mo

POCI⭐Phase 3$24M

PRAX-562 Phase 3 Results Expected

PRAX-562• SCN2A Encephalopathy100

Mar 23

CT.gov

00%

2mo

OTSKF⭐Phase 3$34.0B

Centanafadine Hydrochloride Phase 3 Results Expected

Centanafadine Hydrochloride• Attention-Deficit/Hyperactivity Disorder680

Mar 25

CT.gov

00%

2mo

MLTX⭐Phase 3$1.1B

Sonelokimab Phase 3 Results Expected

Sonelokimab• Hidradenitis Suppurativa35

Mar 27

CT.gov

00%

2mo

AZN.L⭐Phase 3$217.4B

Carboplatin Phase 3 Results Expected

Carboplatin• Locally Advanced or Metastatic Non-Small Cell Lung Cancer454

Mar 30

CT.gov

00%

2mo

NOVN.SW⭐Phase 3$221.6B

Remibrutinib Phase 3 Results Expected

Remibrutinib• Chronic Inducible Urticaria364

Mar 30

CT.gov

00%

2mo

BIO-B⭐Phase 3$9.7B

PJ009 Phase 3 Results Expected

PJ009• Short Bowel Syndrome72

Mar 30

CT.gov

00%

2mo

AZN.L⭐Phase 3$217.4B

Cisplatin Phase 3 Results Expected

Cisplatin• Muscle Invasive Bladder Cancer454

Mar 30

CT.gov

00%

2mo

ROCHE⭐Phase 3

Endocrine Therapy of Physician's Choice Phase 3 Results Expected

Endocrine Therapy of Physician's Choice• Early Breast Cancer4,200

Mar 31

CT.gov

00%

2mo

4503.T⭐Phase 3$4.0T

Fezolinetant Phase 3 Results Expected

Fezolinetant• Menopause277

Mar 31

CT.gov

00%

2mo

NVS⭐Phase 3$274.7B

Placebo Phase 3 Results Expected

NVA237• Chronic Obstructive Pulmonary Disease422

Mar 31

CT.gov

00%

2mo

NVS⭐Phase 3$274.7B

TQJ230 Phase 3 Results Expected

TQJ230• Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease422

Mar 31

CT.gov

00%

2mo

URGN⭐Phase 3$675M

UGN-104 Phase 3 Results Expected

UGN-104• Upper Urinary Tract Urothelial Carcinoma50

Mar 31

CT.gov

00%

2mo

ROCHE⭐Phase 3

Giredestrant Phase 3 Results Expected

Giredestrant• Endometrial Cancer4,200

Mar 31

CT.gov

00%

April 202625

2mo

JNGHF⭐Phase 3

Capecitabine tablets Phase 3 Results Expected

Capecitabine tablets• Breast Cancer400

Apr 1

CT.gov

00%

2mo

JNGHF⭐Phase 3

JSKN003 Phase 3 Results Expected

JSKN003• Advanced Solid Tumor400

Apr 1

CT.gov

00%

2mo

AMLX⭐Phase 3$117.6B

AMX0035 Phase 3 Results Expected

AMX0035• Amyotrophic Lateral Sclerosis110

Apr 1

CT.gov

00%

2mo

VRDN⭐Phase 3$732M

VRDN-003 Phase 3 Results Expected

VRDN-003• Thyroid Eye Disease195

Apr 1

CT.gov

00%

2mo

PRTX⭐Phase 3

Open-label rusfertide Phase 3 Results Expected

Open-label rusfertide• Polycythemia Vera46

Apr 1

CT.gov

00%

2mo

JNGHF⭐Phase 3

Apatinib Mesylate Phase 3 Results Expected

Apatinib Mesylate• Gastric Cancer550

Apr 1

CT.gov

00%

2mo

JNGHF⭐Phase 3

camrelizumab Phase 3 Results Expected

Camrelizumab• Solid Tumor550

Apr 1

CT.gov

00%

2mo

INCY⭐Phase 3$9.9B

Lenalidomide Phase 3 Results Expected

Lenalidomide• Large B-Cell Lymphoma82

Apr 1

CT.gov

00%

2mo

INCY⭐Phase 3$9.9B

Tafasitamab Phase 3 Results Expected

Tafasitamab• Diffuse Large B Cell Lymphoma82

Apr 1

CT.gov

00%

2mo

NOVN.SW⭐Phase 3$221.6B

placebo Phase 3 Results Expected

Vildagliptin 50 mg bid• Type 2 Diabetes Mellitus100

Apr 2

CT.gov

00%

2mo

NOVN.SW⭐Phase 3$221.6B

LOU064 (blinded) Phase 3 Results Expected

LOU064 (blinded)• Chronic Spontaneous Urticaria100

Apr 2

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

fluorouracil Phase 3 Results Expected

fluorouracil• Colorectal Cancer400

Apr 3

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

cetuximab Phase 3 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)400

Apr 3

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

oxaliplatin Phase 3 Results Expected

oxaliplatin• Colorectal Neoplasms400

Apr 3

CT.gov

00%

2mo

PFE⭐Phase 3$142.7B

tucatinib Phase 3 Results Expected

tucatinib• HER2-positive Breast Cancer400

Apr 3

CT.gov

00%

2mo

SNY⭐Phase 3$115.3B

Isatuximab SAR650984 Phase 3 Results Expected

Isatuximab SAR650984• Multiple Myeloma475

Apr 5

CT.gov

00%

2mo

SNY⭐Phase 3$115.3B

Bortezomib Phase 3 Results Expected

Bortezomib• Plasma Cell Myeloma475

Apr 5

CT.gov

00%

2mo

UCBJY⭐Phase 3$57.1B

Staccato alprazolam Phase 3 Results Expected

Staccato alprazolam• Stereotypical Prolonged Seizures350

Apr 6

CT.gov

00%

3mo

ABBV⭐Phase 3$300.2B

OnabotulinumtoxinA Phase 3 Results Expected

OnabotulinumtoxinA• Forehead Lines150

Apr 15

CT.gov

00%

3mo

GILD⭐Phase 3$60.0B

B/F/TAF Phase 3 Results Expected

B/F/TAF• HIV-1-infection609

Apr 15

CT.gov

00%

3mo

ABBV⭐Phase 3$300.2B

ABBV-951 Phase 3 Results Expected

ABBV-951• Parkinson's Disease (PD)130

Apr 15

CT.gov

00%

3mo

LPCN⭐Phase 3$43M

LPCN 1154A Phase 3 Results Expected

LPCN 1154A• Depression, Postpartum80

Apr 15

CT.gov

00%

3mo

ZEAL⭐Phase 3

glepaglutide Phase 3 Results Expected

Glepaglutide• Short Bowel Syndrome145

Apr 15

CT.gov

00%

3mo

ZEAL.CO⭐Phase 3$28.7B

Glepaglutide Phase 3 Results Expected

glepaglutide• Short Bowel Syndrome129

Apr 15

CT.gov

00%

3mo

VTGN⭐Phase 3$81M

Fasedienol Nasal Spray Phase 3 Results Expected

Fasedienol Nasal Spray• Social Anxiety Disorder (SAD)236

Apr 15

CT.gov

00%

Get Phase 3 Clinical Trials Alerts

About Phase 3 Clinical Trials

Late-stage Phase 3 clinical trial results and data readouts for biotech companies.

What is a Phase 3 Clinical Trial?

Phase 3 trials are large-scale studies that test a drug's efficacy and safety in hundreds to thousands of patients. Positive Phase 3 results typically lead to regulatory submission, while negative results can end a drug's development.